Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study

AIM: To evaluate the safety of efpeglenatide, a long‐acting glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), and its effects on body weight management in adults without diabetes. MATERIALS AND METHODS: In this phase II, randomized, placebo‐controlled, double‐blind trial, participants with a body...

Descripción completa

Detalles Bibliográficos
Autores principales: Pratley, Richard E., Kang, Jahoon, Trautmann, Michael E., Hompesch, Marcus, Han, OakPil, Stewart, John, Sorli, Christopher H., Jacob, Stephan, Yoon, Kun‐Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851541/
https://www.ncbi.nlm.nih.gov/pubmed/31264757
http://dx.doi.org/10.1111/dom.13824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851541/
https://www.ncbi.nlm.nih.gov/pubmed/31264757
http://dx.doi.org/10.1111/dom.13824

Ejemplares similares